Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Case report: Non-invasive cyto-salivary sampling and biomarker detection via ELISA versus histopathology for diagnosing oral potentially malignant disorders - Insights from a case-control study.
Rebaudi F, Rebaudi A, De Rosa A, Rebaudi AL, Pesce S, Greppi M, Roghi M, Boggio M, Candiani S, Marcenaro E. Rebaudi F, et al. Among authors: de rosa a. Front Immunol. 2024 Nov 29;15:1477477. doi: 10.3389/fimmu.2024.1477477. eCollection 2024. Front Immunol. 2024. PMID: 39676869 Free PMC article.
A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans.
Rebaudi F, De Rosa A, Greppi M, Pistilli R, Pucci R, Govoni FA, Iacoviello P, Broccolo F, Tomasello G, Pesce S, Laganà F, Bianchi B, Di Gaudio F, Rebaudi A, Marcenaro E. Rebaudi F, et al. Among authors: de rosa a. Front Immunol. 2023 Jul 6;14:1216107. doi: 10.3389/fimmu.2023.1216107. eCollection 2023. Front Immunol. 2023. PMID: 37483588 Free PMC article.
Comparative study of the anaesthetic efficacy of 4% articaine versus 2% mepivacaine in mandibular third molar germectomy using different anaesthetic techniques: a split-mouth clinical trial.
Menditti D, Boccellino M, Nucci L, Ribeiro Sobrinho AP, Marotta A, Angrisani P, Cantore S, Menditti M, Vitiello A, DI Domenico M, Rinaldi B, DE Rosa A. Menditti D, et al. Among authors: de rosa a. Minerva Dent Oral Sci. 2023 Feb;72(1):37-44. doi: 10.23736/S2724-6329.22.04720-9. Minerva Dent Oral Sci. 2023. PMID: 36847742 Clinical Trial.
Report of the Italian Cohort with Activated Phosphoinositide 3-Kinase δ Syndrome in the Target Therapy Era.
Barzaghi F, Moratti M, Panza G, Rivalta B, Giardino G, De Rosa A, Baselli LA, Chinello M, Marzollo A, Montin D, Marinoni M, Costagliola G, Ricci S, Lodi L, Martire B, Milito C, Trizzino A, Tommasini A, Zecca M, Badolato R, Cancrini C, Lougaris V, Pignata C, Conti F. Barzaghi F, et al. Among authors: de rosa a. J Clin Immunol. 2024 Dec 23;45(1):58. doi: 10.1007/s10875-024-01835-1. J Clin Immunol. 2024. PMID: 39714594 Free PMC article.
Clinical trial eligibility in PSP: Population representativeness and potential criteria adjustment based on PSP-NET findings.
Abate F, Di Biasio F, Marchese R, Markushi TB, Ciammola A, Ticozzi N, Calandra-Buonaura G, Cani I, Sambati L, Fabbrini G, Costanzo M, Soricelli A, Frosini D, Del Prete E, Schirinzi T, Stefani A, Borroni B, Padovani A, Barone P, Picillo M, Pilotto A; PSP-NET study group. Abate F, et al. Parkinsonism Relat Disord. 2024 Dec 10;131:107226. doi: 10.1016/j.parkreldis.2024.107226. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 39700727
Psychometric properties and clinical correlates of the Frontal Behaviour Inventory in progressive supranuclear palsy: data from the PSP-NET.
Cappiello A, Cuoco S, De Micco R, Satolli S, Di Biasio F, Markushi TB, Sambati L, Pilotto A, Costanzo M, Longo C, Schirinzi T, Del Prete E, Frosini D, Stefani A, Malaguti MC, Fabbrini G, Padovani A, Calandra-Buonaura G, Marchese R, Tessitore A, Barone P, Picillo M; P. S. P.-N. E. T. study group. Cappiello A, et al. Neurol Sci. 2024 Nov 23. doi: 10.1007/s10072-024-07887-w. Online ahead of print. Neurol Sci. 2024. PMID: 39579261
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.
Lo Prinzi F, Salani F, Rimini M, Rizzato MD, Antonuzzo L, Camera S, Satake T, Vandeputte H, Vivaldi C, Pressiani T, Lucchetti J, Kim JW, Abidoye O, Rapposelli IG, Tamberi S, Finkelmeier F, Giordano G, Pircher C, Chon HJ, Braconi C, Pastorino A, Castet F, Tamburini E, Yoo C, Parisi A, Diana A, Scartozzi M, Prager GW, Avallone A, Schirripa M, Kim IH, Perkhofer L, Oneda E, Verrico M, Adeva J, Chan SL, Spinelli GP, Personeni N, Garajova I, Rodriquenz MG, Leo S, Melo Alvim C, Roque R, Fornaro L, De Rosa A, Lavacchi D, Rossari F, Ikeda M, Dekervel J, Niger M, Balsano R, Tonini G, Kang M, Bekaii-Saab T, Viola MG, Silvestro L, Esposito L, Boccaccino A, Himmelsbach V, Landriscina M, Ahcene Djaballah S, Zanuso V, Masi G, Lonardi S, Rimassa L, Casadei-Gardini A. Lo Prinzi F, et al. Among authors: de rosa a. Oncologist. 2024 Oct 19:oyae256. doi: 10.1093/oncolo/oyae256. Online ahead of print. Oncologist. 2024. PMID: 39427227 Free article.
581 results